Disclosed are 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide derivatives and prodrugs of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof； wherein: R1 is: SO3M, SO2NH2, PO3M, CH2COOM, CF2COOM, CHFCOOM, or CF3； M is hydrogen or a cation； R2 is: hydrogen, (CH2)n-R3, or COOR3； R3 is: hydrogen, optionally substituted alkyl, CN, NR6R7, CONR6R7, NHCONR6R7, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or OR8； and wherein the remaining substituents are as defined herein, and wherein said alkyl is a branched or unbranched saturated acyclic hydrocarbon radical with 1 to 6 carbon atoms； said cycloalkyl is a three to seven member saturated or unsaturated cyclic hydrocarbon radical； said heterocyclyl is a four to seven member cycloalkyl group containing one or more heteroatoms selected from nitrogen, oxygen or sulfur； said aryl is a monocyclic or polycyclic aromatic hydrocarbon containing six to fourteen ring atoms； and said heteroaryl is a monocyclic or polycyclic aromatic hydrocarbon wherein one or more carbon atoms have been replaced with heteroatoms selected from nitrogen, oxygen, or sulfur. Representative compounds include (2S,5R)-N-{ [(2S,4R)-4-trifluoroacetylamino-pyrrolidin-2-yl]methyloxy} -7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, (2S,5R)-N-{ [(2S)-1-carbamimidoyl-pyrrolidin-2-yl]methyloxy} -7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, (2S,5R)-7-oxo-N-{ [(2S)-5-oxopyrrolidin-2-yl]methyloxy} -6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide, (2S,5R)-7-oxo-N-{ [(4S)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazol-4-yl]methyloxy} -6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, (2S,5R)-7-oxo-N-[(2S)-pyrrolidin-2-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, (2S,5R)-N-{ [(2S,4R)-4-hydroxyl-pyrrolidin-2-yl]methyloxy} -7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octa
